Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2024 - 2025)

Aclaris Therapeutics has reported Non-Current Deffered Revenue over the past 2 years, most recently at $16.2 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $16.2 million for Q4 2025, down 19.31% from a year ago — trailing twelve months through Dec 2025 was $16.2 million (down 19.31% YoY), and the annual figure for FY2025 was $16.2 million, down 19.31%.
  • Non-Current Deffered Revenue for Q4 2025 was $16.2 million at Aclaris Therapeutics, down from $17.5 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ACRS hit a ceiling of $21.2 million in Q3 2024 and a floor of $16.2 million in Q4 2025.